At the news
? BULLISHIMPACT 7/10 8-K filed May 4, 2026 at 07:21 ET
Twist Bioscience reported fiscal Q2 2026 revenue of $110.7M, a 19% YoY increase and above the prior quarter's $103.7M, while raising full-year FY2026 revenue guidance to $442M-$447M from $435M-$440M. GAAP net loss widened to $0.71/share from $0.66/share a year ago due to a $7.2M litigation settlement charge, but adjusted EBITDA improved to -$13.3M from -$14.8M. The company reiterated its Q4 FY2026 adjusted EBITDA breakeven target, and both DSPS (+28%) and NGS (+12%) segments showed strong growth.
- Q2 FY2026 revenue of $110.7M, up 19% YoY from $92.8M, exceeding the prior quarter's $103.7M and the company's own guidance
- Full-year FY2026 revenue guidance raised to $442M-$447M from $435M-$440M, implying 17%-19% YoY growth
- Q3 FY2026 revenue guided to ~$114M-$115M, ~19% YoY growth at the midpoint
- GAAP net loss per share was -$0.71 vs -$0.66 a year ago, including a $7.2M litigation settlement charge
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access